Benign Prostatic Hyperplasia (Investigational Adjunct)

Investigational adjunct for symptomatic benign prostatic hyperplasia; alpha-blockers, 5-alpha-reductase inhibitors, and minimally invasive surgical therapy remain evidence-based.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?: Not FDA-cleared for benign prostatic hyperplasia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
Welche Evidenz existiert?: Tier C (investigational). Only a single uncontrolled case-series reference exists; there are no randomized controlled trials. Evidence-based first-line therapy per AUA is alpha-blockers (tamsulosin, alfuzosin, silodosin) for symptom relief, 5-alpha-reductase inhibitors (finasteride, dutasteride) for prostate-volume reduction in larger glands, and combination therapy for moderate-to-severe disease. PDE5 inhibitors (tadalafil) help with concurrent erectile dysfunction. Minimally invasive surgical therapies (TURP, holmium laser enucleation, GreenLight laser, UroLift, Rezum, prostatic artery embolization) are highly effective and well-evidenced for medical-refractory disease.
Hauptrisiken: Bleeding from bite sites for 6 to 24 hours after detachment
Bruising and tenderness over the suprapubic or perineal area for 5 to 10 days
Local skin infection or, rarely, Aeromonas infection
Allergic reaction to leech saliva (uncommon)
Temporary worsening of urinary symptoms for 1 to 3 days
Risk of orthostasis or hypotension if cumulative blood loss is significant on alpha-blocker therapy
Delay or replacement of evidence-based alpha-blocker, 5-alpha-reductase inhibitor, or minimally invasive surgery
Failure to address acute retention, recurrent UTI, hematuria, or bladder stones requiring surgical evaluation
Wer dies nicht in Betracht ziehen sollte: Patients in acute urinary retention (surgical / catheter management indicated)
Patients with recurrent UTI attributable to BPH
Patients with hematuria that has not been worked up
Patients with bladder stones, hydronephrosis, or renal insufficiency from BPH (surgical indication)
Patients with suspected prostate cancer (PSA / DRE workup first)
Patients on anticoagulants, with hemophilia, or with severe anemia
Was Sie Ihren Kliniker fragen sollten: What is my IPSS (International Prostate Symptom Score) and bother score?
Has my PSA been checked, and is prostate cancer ruled out?
Have I had post-void residual measurement, uroflowmetry, and (where indicated) bladder ultrasound?
Have I tried alpha-blockers (tamsulosin)? Have 5-alpha-reductase inhibitors been considered if the gland is enlarged?
Am I a candidate for minimally invasive surgery (UroLift, Rezum, TURP, HoLEP, GreenLight)?
Where exactly will leeches be placed — NEVER trans-rectal?
What is the practitioner's experience and Aeromonas-prevention plan?
Wann dringende medizinische Versorgung suchen: Inability to urinate (acute urinary retention — urgent care)
Visible blood in urine, especially with clots
Severe lower abdominal pain with distended bladder
Fever, chills, dysuria, flank pain (UTI or pyelonephritis)
Sudden urinary leakage (overflow incontinence)
Bleeding from a bite site lasting more than 24 to 48 hours
Fever above 38.0 C / 100.4 F or chills
Hives, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

It does not shrink the prostate — only 5-alpha-reductase inhibitors have RCT evidence for that, and only in larger glands.
It does not replace alpha-blockers for symptom relief, which have strong RCT support.
It does not address acute urinary retention, recurrent UTI, hematuria, or bladder stones, all of which need surgical referral.
Only one uncontrolled case-series reference exists; benefit is unsupported.

Sicherheits-Querverweise

Clinical Profile

Category: urogenital
ICD-10: N40.0, N40.1, N40.3
Safety tier: medium

Evidence Summary

Symptomatic benign prostatic hyperplasia (BPH) presents with lower urinary tract symptoms (LUTS): frequency, urgency, weak stream, nocturia, and incomplete emptying. AUA evidence-based first-line pharmacotherapy is alpha-blockers (tamsulosin, alfuzosin) for symptom relief, 5-alpha-reductase inhibitors (finasteride, dutasteride) for gland-volume reduction in larger prostates, combination therapy for moderate-severe disease, and PDE5 inhibitors (tadalafil) for concurrent erectile dysfunction. Minimally invasive surgical therapy (TURP, GreenLight laser, UroLift, Rezum) is highly effective for medical-refractory disease. No published controlled trials or case series of hirudotherapy exist for benign prostatic hyperplasia; any use is investigational only, and the mechanism for any deep prostatic effect from skin placement is speculative.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Acute urinary retention (surgical referral)
Recurrent UTI from BPH
Hematuria not worked up
Bladder stones, hydronephrosis, or renal insufficiency from BPH (surgical indication)
Suspicion of prostate cancer (PSA, DRE workup first)

Related Conditions

Peyronie's Disease (Stable Phase)

Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.

Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)

Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.

Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)

Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.

Interstitial Cystitis / Bladder Pain Syndrome (Investigational)

Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.